683 Phase I first-in-human study on the feasibility, safety, and antitumor activity of CD4-redirected chimeric antigen receptor (CAR) T-cell therapy in patients with CD4+ T-cell malignancies (TCM)

• Robert Emmons,
• Lionel Apetoh,
• Rita Assi,
• Nabil Hagag,
• Sherif Farag,
• Allie Carter,
• Magdalena Czader,
• Rafat Abonnour,
• Yupo Ma,
• Huda Salman

Affiliations

Robert Emmons

4University of Louisville, Louisville, KY, USA

Lionel Apetoh

INSERM, U1231, Dijon, France

Rita Assi

1Indiana University, Indianapolis, IN, USA

Nabil Hagag

2Stony Brook University, Stony Brook, NY, USA

Sherif Farag

3Indiana University School of Medicine, Indianapolis, IN, USA

Allie Carter

1Indiana University, Indianapolis, IN, USA

Magdalena Czader

3Indiana University School of Medicine, Indianapolis, IN, USA

Rafat Abonnour

1Indiana University, Indianapolis, IN, USA

Yupo Ma

2Stony Brook University, Stony Brook, NY, USA

Huda Salman

1Indiana University, Indianapolis, IN, USA